MMSI stock icon

Merit Medical Systems
MMSI

$96.58
0.85%

Market Cap: $5.61B

 

About: Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.

Employees: 6,950

0
Funds holding %
of 6,686 funds
0
Analysts bullish %
of 9 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

7,002% more call options, than puts

Call options by funds: $75.7M | Put options by funds: $1.07M

48% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 33

24% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 101

16% more capital invested

Capital invested by funds: $4.5B [Q1] → $5.21B (+$709M) [Q2]

5% more funds holding

Funds holding: 301 [Q1] → 317 (+16) [Q2]

1.71% more ownership

Funds ownership: 102.67% [Q1] → 104.39% (+1.71%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$92
5%
downside
Avg. target
$101
4%
upside
High target
$125
29%
upside

9 analyst ratings

positive
89%
neutral
11%
negative
0%
Needham
Mike Matson
64% 1-year accuracy
72 / 113 met price target
9%upside
$105
Buy
Maintained
28 Aug 2024
B of A Securities
Craig Bijou
75% 1-year accuracy
3 / 4 met price target
5%downside
$92
Neutral
Maintained
5 Aug 2024
Piper Sandler
Jason Bednar
45% 1-year accuracy
18 / 40 met price target
4%upside
$100
Overweight
Maintained
2 Aug 2024
Needham
Mike Matson
64% 1-year accuracy
72 / 113 met price target
3%downside
$94
Buy
Maintained
2 Aug 2024
Barrington Research
Michael Petusky
62% 1-year accuracy
31 / 50 met price target
4%upside
$100
Outperform
Maintained
16 Jul 2024

Financial journalist opinion